Trial Progress

The PREDICT‑1 genotype‑based registrational trial of Licaminlimab in dry eye disease (DED) continues with enrollment progressing as planned, and all sites activated, exceeding 45 % patient randomization. The FDA's pre‑IND feedback also supports the proposed clinical development strategy for Privosegtor in optic neuritis.